Analysts Set DRI Healthcare Trust (TSE:DHT.UN) Price Target at C$21.83

DRI Healthcare Trust (TSE:DHT.UN) has received an average recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is C$21.83.

DHT.UN has been the subject of several recent research reports. National Bankshares boosted their price objective on DRI Healthcare Trust from C$22.00 to C$23.50 and gave the stock an “outperform” rating in a report on Friday, March 1st. CIBC boosted their price objective on DRI Healthcare Trust from C$19.00 to C$19.50 and gave the stock an “outperform” rating in a report on Friday, March 1st. Scotiabank upped their price target on DRI Healthcare Trust from C$22.00 to C$24.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Raymond James raised DRI Healthcare Trust from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from C$22.00 to C$24.00 in a research note on Friday, March 1st. Finally, Stifel Nicolaus upped their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company a “buy” rating in a research note on Friday, March 1st.

DRI Healthcare Trust Price Performance

DRI Healthcare Trust stock opened at C$16.84 on Wednesday. The firm has a 50-day simple moving average of C$15.75. DRI Healthcare Trust has a 12-month low of C$7.55 and a 12-month high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.